Tolremo
TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges
- Website
- tolremo.com
- Total Funding
- $17.1M
- Last Round
- $5.9M Extension RoundSep 2023
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.
About
preventing resistance to cancer therapy
Summary
Tolremo is a Biotech company. It has raised $17.1M in total across 2 rounds, most recently a $5.9M Extension Round in Sep 2023. Investors include BioMedPartners and Redalpine.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sep 2023
Sign up to see all 2 events
Funding: Series A through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/tolremo"><img src="https://indexed.vc/api/badge/company/tolremo" alt="Tolremo on Indexed.vc" width="260" height="76" /></a>